Changes in the symptom pattern and the densities of large-intestinal endocrine cells following Campylobacter infection in irritable bowel syndrome: A case report

BMC Research Notes

Volumn 6, Issue 1, 2013, Pages

  El Salhy, Magdy ^a,c   Mazzawi, Tarek ^a,c   Gundersen, Doris ^b   Hatlebakk, Jan G ^c   Hausken, Trygve ^c  

^a Stord Helse Fonna Hospital   (Norway)

^b Helse Fonna ^*  (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

Campylobacter; Irritable bowel syndrome; Peptide YY; Quality of life; Serotonin; Somatostatin

Indexed keywords

CAMPYLOBACTER;

SEROTONIN;

ARTICLE; CAMPYLOBACTER; CAMPYLOBACTERIOSIS; CASE REPORT; CELL COUNT; ENDOCRINE CELL; FEMALE; HUMAN; INTESTINE MUCOSA; IRRITABLE COLON; LARGE INTESTINE; LEUKOCYTE; MAST CELL; METABOLISM; MICROBIOLOGY; PATHOLOGY; QUALITY OF LIFE; RECTUM; YOUNG ADULT;

CAMPYLOBACTER; CAMPYLOBACTER INFECTIONS; CELL COUNT; ENDOCRINE CELLS; FEMALE; HUMANS; INTESTINAL MUCOSA; INTESTINE, LARGE; IRRITABLE BOWEL SYNDROME; LEUKOCYTES; MAST CELLS; QUALITY OF LIFE; RECTUM; SEROTONIN; YOUNG ADULT;

EID: 84884624366     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-6-391     Document Type: Article

References (57)

1. Chromogranin a cell density as a diagnostic marker for lymphocytic colitis. El-Salhy M, Gundersen D, Hatlebakk JG, Hausken T, Dig Dis Sci 2012 57 3154 3159 10.1007/s10620-012-2249-6 22699394
2. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Agreus L, Svardsudd K, Nyren O, Tibblin G, Gastroenterology 1995 109 671 680 10.1016/0016-5085(95)90373-9 7657095
3. Functional bowel disorders in apparently healthy people. Thompson WG, Heaton KW, Gastroenterology 1980 79 283 288 7399231 (Pubitemid 10046370)
4. U.S. householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E, et al. Dig Dis Sci 1993 38 1569 1580 10.1007/BF01303162 8359066 (Pubitemid 23271409)
5. An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome. Spiller R, Lam C, J Neurogastroenterol Motil 2012 18 3 258 268 10.5056/jnm.2012.18.3.258 22837873
6. Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? a prospective, community-based, case-control study. Parry SD, Stansfield R, Jelley D, Gregory W, Phillips E, Barton JR, Welfare MR, Am J Gastroenterol 2003 98 1970 1975 14499773 (Pubitemid 37185791)
7. Risk factors for sporadic campylobacter infection in the United States: a case-control study in foodnet sites. Friedman CR, Hoekstra RM, Samuel M, Marcus R, Bender J, Shiferaw B, Reddy S, Ahuja SD, Helfrick DL, Hardnett F, et al. Clin Infect Dis 2004 38 Suppl 3 285 296 15095201
8. Risk factors for sporadic campylobacter infections: results of a case-control study in southeastern Norway. Kapperud G, Skjerve E, Bean NH, Ostroff SM, Lassen J, J Clin Microbiol 1992 30 3117 3121 1452694
9. Postinfectious irritable bowel syndrome. Spiller R, Garsed K, Gastroenterology 2009 136 1979 1988 10.1053/j.gastro.2009.02.074 19457422
10. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. Neal KR, Hebden J, Spiller R, BMJ 1997 314 7083 779 782 10.1136/bmj.314.7083.779 9080994 (Pubitemid 27117047)
11. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR, Gut 2000 47 804 811 10.1136/gut.47.6.804 11076879
12. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Wang LH, Fang XC, Pan GZ, Gut 2004 53 8 1096 1101 10.1136/gut.2003.021154 15247174 (Pubitemid 38961961)
13. Irritable bowel syndrome: the role of gut neuroendocrine peptides. El-Salhy M, Seim I, Chopin L, Gundersen D, Hatlebakk JG, Hausken T, Front Biosci (Elite Ed) 2012 4 2783 2800
14. Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. El-Salhy M, Gundersen D, Ostgaard H, Lomholt-Beck B, Hatlebakk JG, Hausken T, Dig Dis Sci 2012 57 873 878 10.1007/s10620-011- 1948-8 22057239
15. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Dunlop SP, Coleman NS, Blackshaw E, Perkins AC, Singh G, Marsden CA, Spiller RC, Clin Gastroenterol Hepatol 2005 3 349 357 10.1016/S1542-3565(04) 00726-8 15822040 (Pubitemid 40488343)
16. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Dunlop SP, Jenkins D, Neal KR, Spiller RC, Gastroenterology 2003 125 1651 1659 10.1053/j.gastro.2003.09.028 14724817 (Pubitemid 37500429)
17. Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction. Wheatcroft J, Wakelin D, Smith A, Mahoney CR, Mawe G, Spiller R, Neurogastroenterol Motil 2005 17 863 870 10.1111/j.1365-2982.2005.00719.x 16336502 (Pubitemid 41748282)
18. Evaluation of the Birmingham IBS symptom questionnaire. Roalfe AK, Roberts LM, Wilson S, BMC gastroenterology 2008 8 30 10.1186/1471-230X-8-30 18651941
19. Quality of life in functional dyspepsia: responsiveness of the Nepean Dyspepsia Index and development of a new 10-item short form. Talley NJ, Verlinden M, Jones M, Aliment Pharmacol Ther 2001 15 2 207 216 10.1046/j.1365-2036.2001.00900.x 11148439 (Pubitemid 32142498)
20. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL, Dig Dis Sci 1998 43 2 400 411 10.1023/A:1018831127942 9512138 (Pubitemid 28124621)
21. Effects of a health program comprising reassurance, diet management, probiotics administration and regular exercise on symptoms and quality of life in patients with irritable bowel syndrome. El-Salhy M, Lillebo E, Reinemo A, Salmelid L, Hausken T, Gastroenterology insights 2010 2 21 26
22. Chromogranin A as a possible tool in the diagnosis of irritable bowel syndrome. El-Salhy M, Lomholt-Beck B, Hausken T, Scand J Gastroenterol 2010 45 1435 1439 10.3109/00365521.2010.503965 20602602
23. Chromogranin A cell density in the rectum of patients with irritable bowel syndrome. El-Salhy M, Mazzawi T, Gundersen D, Hausken T, Mol Med Report 2012 6 1223 1225
24. Chromogranin A (CgA) in the gastro-entero-pancreatic (GEP) endocrine system II. CgA in mammalian entero-endocrine cells. Cetin Y, Muller-Koppel L, Aunis D, Bader MF, Grube D, Histochemistry 1989 92 4 265 275 10.1007/BF00500540 2807986 (Pubitemid 19213171)
25. Ageing and endocrine cells of human duodenum. Sandstrom O, El-Salhy M, Mech Ageing Dev 1999 108 39 48 10.1016/S0047-6374(98)00154-7 10366038 (Pubitemid 29210238)
26. Terminal ileal mucosal mast cells in irritable bowel syndrome. Weston AP, Biddle WL, Bhatia PS, Miner PB Jr, Dig Dis Sci 1993 38 1590 1595 10.1007/BF01303164 8359068 (Pubitemid 23271411)
27. Increased mast cells in the irritable bowel syndrome. O'Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A, O'Morain CA, Neurogastroenterol Motil 2000 12 449 457 10.1046/j.1365-2982.2000.00221.x 11012945
28. Relative importance of abnormalities of CCK and 5-HT (serotonin) in Giardia-induced post-infectious irritable bowel syndrome and functional dyspepsia. Dizdar V, Spiller R, Singh G, Hanevik K, Gilja OH, El-Salhy M, Hausken T, Aliment Pharmacol Ther 2010 31 883 891 20132151
29. Distinctive clinical, pyschological, and histological features of postinfective irritable bowel syndrome. Dunlop SP, Jenkins D, Spiller RC, Am J Gastroenterol 2003 98 1578 1583 10.1111/j.1572-0241.2003.07542.x 12873581 (Pubitemid 36875351)
30. Increased immunoendocrine cells in intestinal mucosa of postinfectious irritable bowel syndrome patients 3 years after acute Shigella infection- an observation in a small case control study. Kim HS, Lim JH, Park H, Lee SI, Younsei Med J 2010 51 45 51 10.3349/ymj.2010.51.1.45
31. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK, Cho SW, J Gastroenterol Hepatol 2008 23 1689 1694 10.1111/j.1440-1746.2008.05574.x 19120860
32. Mast cells and inflammatory mediators in chronic ulcerative colitis. Stoyanova II, Gulubova MV, Acta histochemica 2002 104 2 185 192 10.1078/0065-1281-00641 12086339 (Pubitemid 34606365)
33. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H, Crowell MD, Sharkey KA, Gershon MD, Mawe GM, et al. Gastroenterology 2004 126 1657 1664 10.1053/j.gastro.2004.03.013 15188158 (Pubitemid 38736329)
34. Peptide YY abnormalities in patients with ulcerative colitis. Tari A, Teshima H, Sumii K, Haruma K, Ohgoshi H, Yoshihara M, Kajiyama G, Miyachi Y, Japanese journal of medicine 1988 27 1 49 55 10.2169/internalmedicine1962.27.49 3367539
35. High densities of serotonin and peptide YY cells in the colon of patients with lymphocytic colitis. El-Salhy M, Gundersen D, Hatlebakk JG, Hausken T, World J Gastroenterol 2012 18 42 6070 6075 10.3748/wjg.v18.i42.6070 23155335
36. Gut hormones: emerging role in immune activation and inflammation. Khan WI, Ghia JE, Clin Exp Immunol 2010 161 19 27 20408856
37. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gershon MD, Tack J, Gastroenterology 2007 132 397 414 10.1053/j.gastro.2006.11.002 17241888 (Pubitemid 46127672)
38. Actions of 5-hydroxytryptamine on myenteric neurons in guinea pig gastric antrum. Tack JF, Janssens J, Vantrappen G, Wood JD, Am J Physiol 1992 263 838 846 1476191
39. Plasticity in serotonin control mechanisms in the gut. Gershon MD, Curr Opin Pharmacol 2003 3 600 607 10.1016/j.coph.2003.07.005 14644011 (Pubitemid 37451867)
40. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Gershon MD, Curr Opin Endocrinol Diabetes Obes 2013 20 14 21 10.1097/MED. 0b013e32835bc703 23222853
41. Serotonin is a sword and a shield of the bowel: serotonin plays offense and defense. Gershon MD, Trans Am Clin Climatol Assoc 2012 123 268 280 discussion 280 23303993
42. Subpopulations of gastric myenteric neurons are differentially activated via distinct serotonin receptors: projection, neurochemical coding, and functional implications. Michel K, Sann H, Schaaf C, Schemann M, J Neurosci 1997 17 8009 8017 9315919 (Pubitemid 27426236)
43. The ileal brake-inhibition of jejunal motility after ileal fat perfusion in man. Spiller RC, Trotman IF, Higgins BE, Ghatei MA, Grimble GK, Lee YC, Bloom SR, Misiewicz JJ, Silk DB, Gut 1984 25 365 374 10.1136/gut.25.4.365 6706215 (Pubitemid 14136456)
44. Effect of infusion of nutrient solutions into the ileum on gastrointestinal transit and plasma levels of neurotensin and enteroglucagon. Read NW, McFarlane A, Kinsman RI, Bates TE, Blackhall NW, Farrar GB, Hall JC, Moss G, Morris AP, O'Neill B, et al. Gastroenterology 1984 86 274 280 6690354 (Pubitemid 14218579)
45. The peptide YY-preferring receptor mediating inhibition of small intestinal secretion is a peripheral Y(2) receptor: pharmacological evidence and molecular cloning. Goumain M, Voisin T, Lorinet AM, Ducroc R, Tsocas A, Roze C, Rouet-Benzineb P, Herzog H, Balasubramaniam A, Laburthe M, Mol Pharmacol 2001 60 124 134 11408607 (Pubitemid 32595240)
46. Several receptors mediate the antisecretory effect of peptide YY, neuropeptide Y, and pancreatic polypeptide on VIP-induced fluid secretion in the rat jejunum in vivo. Souli A, Chariot J, Voisin T, Presset O, Tsocas A, Balasubramaniam A, Laburthe M, Roze C, Peptides 1997 18 551 557 10.1016/S0196-9781(97)00069-7 9210175 (Pubitemid 27273751)
47. Antisecretory mechanisms of peptide YY in rat distal colon. Whang EE, Hines OJ, Reeve JR Jr, Grandt D, Moser JA, Bilchik AJ, Zinner MJ, McFadden DW, Ashley SW, Dig Dis Sci 1997 42 1121 1127 10.1023/A:1018869116284 9201071 (Pubitemid 27343433)
48. NPY Y2 receptor agonist PYY(3-36) inhibits diarrhea by reducing intestinal fluid secretion and slowing colonic transit in mice. Moriya R, Shirakura T, Hirose H, Kanno T, Suzuki J, Kanatani A, Peptides 2010 31 671 675 10.1016/j.peptides.2009.11.005 19925840
49. A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. Drossman DA, Morris CB, Hu Y, Toner BB, Diamant N, Leserman J, Shetzline M, Dalton C, Bangdiwala SI, Gastroenterology 2005 128 3 580 589 10.1053/j.gastro.2004.12.006 15765393 (Pubitemid 40585359)
50. Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype. Mearin F, Balboa A, Badia X, Baro E, Caldwell E, Cucala M, Diaz-Rubio M, Fueyo A, Ponce J, Roset M, et al. Eur J Gastroenterol Hepatol 2003 15 2 165 172 10.1097/00042737-200302000-00010 12560761 (Pubitemid 36269781)
51. Clinical patterns over time in irritable bowel syndrome: symptom instability and severity variability. Mearin F, Baro E, Roset M, Badia X, Zarate N, Perez I, Am J Gastroenterol 2004 99 113 121 10.1046/j.1572-0241.2003.04023.x 14687152 (Pubitemid 38679112)
52. Fluctuation of gastrointestinal symptoms in the community: a 10-year longitudinal follow-up study. Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P, Aliment Pharmacol Ther 2008 28 1013 1020 10.1111/j.1365-2036.2008.03813.x 18657131
53. Acute infective colitis caused by endemic pathogens in western Europe: endoscopic features. Rutgeerts P, Geboes K, Ponette E, Coremans G, Vantrappen G, Endoscopy 1982 14 212 219 10.1055/s-2007-1021624 7140655 (Pubitemid 13235944)
54. To "lump" or to "split" the functional somatic syndromes: can infectious and emotional risk factors differentiate between the onset of chronic fatigue syndrome and irritable bowel syndrome? Moss-Morris R, Spence M, Psychosom Med 2006 68 463 469 10.1097/01.psy.0000221384.07521.05 16738080 (Pubitemid 44297680)
55. The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis. Spence MJ, Moss-Morris R, Gut 2007 56 1066 1071 10.1136/gut.2006.108811 17324974 (Pubitemid 47123235)
56. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM, Gastroenterology 2006 131 445 450 quiz 660 10.1053/j.gastro.2006.05.053 16890598 (Pubitemid 44142459)
57. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebo-controlled study. Quigley EM, Vandeplassche L, Kerstens R, Ausma J, Aliment Pharmacol Ther 2009 29 315 328 10.1111/j.1365-2036.2008.03884.x 19035970